🇺🇸 Stoke Therapeutics, Inc.
Forum topic · STOK · Company page: financials, ownership and filings
Join the discussion on Stoke Therapeutics, Inc.
Loading…
Insider trading in October 2026
Directors and officers of Stoke Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 2 insiders sold shares worth about $44,002 in 2 trades.
Awards, option exercises and shares withheld for tax are not counted.
Results announced on 29 October 2026
Stoke Therapeutics, Inc. announced results on 29 October 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $11 million (up 6% from a year earlier) and a net loss of $74 million.
Mutual funds: 196 funds hold $669 million
196 mutual funds in 1 country hold shares of Stoke Therapeutics, Inc. worth $669 million, about 32.9% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 113 funds added shares and 58 sold; on balance they bought $85 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.